Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study
Portfolio Pulse from
Sage Therapeutics has decided to halt the development of its experimental drug for treating cognitive impairment in Huntington's disease patients after it failed a mid-stage study.
November 20, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sage Therapeutics has stopped the development of its drug for cognitive impairment in Huntington's disease after a failed mid-stage study.
The failure of the mid-stage study for the Huntington's disease drug is a setback for Sage Therapeutics, likely leading to a negative impact on its stock price as investors react to the halted development.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100